PE20050755A1 - Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina - Google Patents

Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina

Info

Publication number
PE20050755A1
PE20050755A1 PE2004000963A PE2004000963A PE20050755A1 PE 20050755 A1 PE20050755 A1 PE 20050755A1 PE 2004000963 A PE2004000963 A PE 2004000963A PE 2004000963 A PE2004000963 A PE 2004000963A PE 20050755 A1 PE20050755 A1 PE 20050755A1
Authority
PE
Peru
Prior art keywords
composition
mycophenolic acid
rapamycin
multiparticles
combination
Prior art date
Application number
PE2004000963A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Becker
Carsten Burger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
Jorg Ogorka
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050755A1 publication Critical patent/PE20050755A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2004000963A 2003-10-03 2004-10-01 Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina PE20050755A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds

Publications (1)

Publication Number Publication Date
PE20050755A1 true PE20050755A1 (es) 2005-11-28

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000963A PE20050755A1 (es) 2003-10-03 2004-10-01 Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina

Country Status (11)

Country Link
US (1) US20070036857A1 (enExample)
EP (1) EP1670437A1 (enExample)
JP (1) JP2007507458A (enExample)
AR (1) AR045957A1 (enExample)
AU (1) AU2004280078B2 (enExample)
BR (1) BRPI0414864A (enExample)
CA (1) CA2538099A1 (enExample)
MX (1) MXPA06003646A (enExample)
PE (1) PE20050755A1 (enExample)
TW (1) TW200520759A (enExample)
WO (1) WO2005034916A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
WO2008060546A2 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Oral formulations
AU2008288106B2 (en) * 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
MX2010009704A (es) * 2008-03-05 2010-12-20 Panacea Biotec Ltd Composiciones farmaceuticas de liberacion modifcada que comprenden micofenolato y procesos de estas.
CA2766009A1 (en) * 2009-06-25 2010-12-29 Danisco A/S Variant lipolytic enzymes with improved expression, functionality and/or activity
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015103447A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
PE20141649A1 (es) * 2011-10-06 2014-11-14 Novartis Ag Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina
US20140105976A1 (en) * 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事(everolimus)之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
WO2016185443A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
AU2017363970A1 (en) 2016-11-23 2019-06-20 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
JP7385474B2 (ja) * 2017-03-13 2023-11-22 オカヴァ ファーマシューティカルズ, インコーポレイテッド 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20250282721A9 (en) * 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
WO2023224914A1 (en) * 2022-05-16 2023-11-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
UA39962C2 (uk) * 1993-10-01 2001-07-16 Сінтекс ( С.Ш.А. ) Інк. Фармацевтична композиція, яка містить мофетил мікофеноляту, для орального введення ( варіанти ) та спосіб її одержання ( варіанти )
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
ID21571A (id) * 1996-10-14 1999-06-24 Hoffmann La Roche Proses pembuatan preparasi bubuk
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
TW200306826A (en) * 2002-01-10 2003-12-01 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
CA2498191C (en) * 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
JP2006501936A (ja) * 2002-10-04 2006-01-19 エラン ファーマ インターナショナル,リミティド 固体ナノ粒子活性薬剤のガンマ線照射
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR045957A1 (es) 2005-11-16
MXPA06003646A (es) 2006-06-05
WO2005034916A1 (en) 2005-04-21
JP2007507458A (ja) 2007-03-29
AU2004280078B2 (en) 2008-08-07
US20070036857A1 (en) 2007-02-15
CA2538099A1 (en) 2005-04-21
AU2004280078A1 (en) 2005-04-21
TW200520759A (en) 2005-07-01
EP1670437A1 (en) 2006-06-21
BRPI0414864A (pt) 2006-11-28

Similar Documents

Publication Publication Date Title
PE20050755A1 (es) Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina
MX2009004439A (es) Composicion de ibuprofeno.
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
ECSP088239A (es) Composición de liberación de fármaco sostenida
WO2007070677A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
BR0209489A (pt) Composições farmacêuticas
CO6400186A2 (es) Tabletas de acetato de ulipristal
BR0210139A (pt) Composições farmacêuticas
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
MX2011013539A (es) Tabletas de farmaco solidas para dispositivos implantables para administrar farmacos.
DK1480624T3 (da) Farmaceutisk tablet
AR037937A1 (es) Composiciones farmaceuticas de agonista parcial de 5ht4
AR061093A1 (es) Composiciones de calcio
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
ECSP088240A (es) Composición de trazodona para administración una vez por día
BRPI0508063A (pt) processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
GT200600500A (es) Composición farmacéutica orodispersable para la administración oromucosal o sublingual de la agomelatina
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
MX2009003169A (es) Derivados de sulfonamida.
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
RU2008147216A (ru) Жидкая лекарственная композиция
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler

Legal Events

Date Code Title Description
FX Voluntary withdrawal